NPM1 Mutation clinical trials at UCSF
1 research study open to eligible people
NPM1 mutation is a genetic alteration seen in leukemia. UCSF is exploring the effects of ziftomenib when given with typical treatments in difficult cases of leukemia. The study checks how well the combination works and if it's safe for these patients.
Showing trials for
Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
open to eligible people ages 18 years and up
The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.
San Francisco, California and other locations
Last updated: